Skip to main content
letter
. 2021 Jun 23:NEJMc2108861. doi: 10.1056/NEJMc2108861

Figure 1. Immunogenicity.

Figure 1

Panel A shows the prevalence of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies before and after vaccination in the study population. Panel B shows anti–SARS-CoV-2 antibody titers before and after vaccination in the study population.